Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
48
WINT Quote, Financials, Valuation and Earnings
Last price:
$1.02
Seasonality move
:
-6.37%
Day range:
$0.65 - $1.06
52-week range:
$0.36 - $737.44
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.42x
P/B ratio:
0.32x
Volume:
49.2M
Avg. volume:
15.4M
1-year change:
-99.51%
Market cap:
$3.3M
Revenue:
--
EPS (TTM):
-$1,261.36
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Windtree Therapeutics has 344.44% upside to fair value with a price target of $4.00 per share.
WINT vs. S&P 500
-
Over the past 5 trading days, Windtree Therapeutics has overperformed the S&P 500 by 33.25% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Windtree Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Windtree Therapeutics revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Windtree Therapeutics reported revenues of --.
Earnings Growth
-
Windtree Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Windtree Therapeutics reported earnings per share of -$4.63.
Enterprise value:
2.7M
EV / Invested capital:
--
Price / LTM sales:
0.42x
EV / EBIT:
--
EV / Revenue:
3.64x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.18x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$17.3M | -$18.2M | -$24.7M | -$4.4M | -$4.1M | |
| EBITDA | -$36.4M | -$5.4M | -$15.6M | $10.4M | -$4M | |
| Diluted EPS | -$120,932.13 | -$1,921.27 | -$1,261.36 | $1,099.37 | -$4.63 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $39.3M | $16.4M | $5.2M | $3.3M | $1.6M | |
| Total Assets | $135.9M | $67.1M | $35.2M | $30.1M | $26.8M | |
| Current Liabilities | $7.5M | $4.8M | $2.8M | $5M | $6.5M | |
| Total Liabilities | $44.4M | $32.4M | $28.2M | $14.7M | $16.5M | |
| Total Equity | $91.5M | $34.7M | $7M | $15.4M | $10.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$15.3M | -$13.9M | -$14.9M | -$2.9M | -$2.4M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $3.8M | $12M | $13.5M | $1M | $1.8M | |
| Free Cash Flow | -$15.3M | -$13.9M | -$14.9M | -$2.9M | -$2.4M | |
WINT
Sector
Market Cap
$3.3M
$34.4M
Price % of 52-Week High
0.12%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-99.52%
-37.36%
Beta (5-Year)
0.703
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.77
200-day SMA
Sell
Level
$14.24
Bollinger Bands (100)
Sell
Level
0.46 - 2.04
Chaikin Money Flow
Sell
Level
-31.3M
20-day SMA
Buy
Level
$0.64
Relative Strength Index (RSI14)
Buy
Level
60.54
ADX Line
Buy
Level
22.49
Williams %R
Neutral
Level
-22.8571
50-day SMA
Buy
Level
$0.72
MACD (12, 26)
Buy
Level
0.20
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
141.7M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Stock Forecast FAQ
In the current month, WINT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The WINT average analyst price target in the past 3 months is $4.00.
-
Where Will Windtree Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Windtree Therapeutics share price will rise to $4.00 per share over the next 12 months.
-
What Do Analysts Say About Windtree Therapeutics?
Analysts are divided on their view about Windtree Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Windtree Therapeutics is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Windtree Therapeutics's Price Target?
The price target for Windtree Therapeutics over the next 1-year time period is forecast to be $4.00 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is WINT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Windtree Therapeutics is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of WINT?
You can purchase shares of Windtree Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Windtree Therapeutics shares.
-
What Is The Windtree Therapeutics Share Price Today?
Windtree Therapeutics was last trading at $1.02 per share. This represents the most recent stock quote for Windtree Therapeutics. Yesterday, Windtree Therapeutics closed at $0.90 per share.
-
How To Buy Windtree Therapeutics Stock Online?
In order to purchase Windtree Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
93
EXOD alert for Jul 18
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
